NCT03125746Unknown1 期
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles and the Antitumor Activity of LXI-15029 Alone or in Combination With Exemestane at Single Ascending Dose and Multiple Ascending Doses in Chinese Patients With Advanced Malignant Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Number of participants with adverse events
研究概览
简要总结
- To evaluate the safety and tolerability of LXI-15029 in Chinese patients with advanced malignant solid tumors in monotherapy period, including confirmation of the maximum tolerated dose (MTD) of monotherapy. 2.To evaluate the safety and tolerability of LXI-15029 in Chinese postmenopausal patients with metastatic or locally advanced breast cancer with estrogen receptor (+) and human epidermal growth factor receptor 2 (-) in combined with Exemestane period , including confirmation of the maximum tolerated dose(MTD) of the combined therapy with Exemestane.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Monotherapy Period
- •Patients with signed written informed consent form;
- •Chinese man or woman, aged 18 to 65 years old;
- •Patient with histologically or cytologically confirmed, advanced solid tumor after failure of standard of care or without standard of care;
- •Patients must have at least one measurable lesion as defined by RECIST v1.1 (during dose escalation phase,no measurable lesion as defined by RECIST v1.1 but evaluable lesion could also been enrolled);
- •Expected survival no less than 12 weeks;
- •Eastern Cooperative Oncology Group (USA) Performance Status 0 to 1;
- •Patient of childbearing potential (regardless of man or woman) who is willing to take contraceptive measures from signature of the informed consent form to 3 months after the last dose of investigational product. Negative serum pregnancy test within 7 days prior to the planned first dose of investigational product for female patient of childbearing potential;
- •Have the ability to communicate with study staff, understand and comply with all the study requirements;
- •Combined with Exemestane period
- •Patients with signed written informed consent form;
- •Chinese patients aged postmenopausal women to 65 years old;
- •Postmenopausal patient;
- •Histologically or cytologically confirmed metastatic or locally advanced breast cancer that is not suitable for surgery or radiotherapy;
- •Estrogen receptor (+), defined as tumor cells with estrogen receptor (+) ≥1% in immunohistochemistry;
- •HER2-negative (Human epithelial growth factor receptor 2-negative) tumor;
- •Measurable lesions in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1;
- •Expected survival no less than 12 weeks;
- •Eastern Cooperative Oncology Group (USA) Performance Status 0 to 1;
- •Have the ability to communicate with study staff, understand and comply with all the study requirements;
排除标准
- •Monotherapy Period:
- •Previous antitumor therapy or any surgical operation within 4 weeks prior to administration of the first dose of study drug;
- •Treatment with myeloid hematopoietic growth factor within 2 weeks prior to use of investigational product;
- •Patients receiving corticosteroids or immunosuppressive agents within 4 weeks prior to administration of the first dose of study drug;
- •Use of potent-to-moderate cytochrome metabolism enzyme CYP3A4 inhibitor and inducer prior to treatment or during washout period;
- •Known allergy to LXI-15029 or similar products (mammalian target of rapamycin (mTOR) inhibitor or dual mTOR inhibitor) or other components of LXI-15029;
- •Previous or receiving of PI3K or mTOR inhibitors (e.g., BKM120, everolimus, AZD8055 or AZD2014, etc.);
- •History, symptoms or signs of spinal compression, brain metastasis or meningeal metastasis, or manifestations of edema or progression in radiology;
- •History of other tumors within 5 years, except cured carcinoma in situ of cervix or cutaneous basal cell carcinoma;
- •The toxicity induced by treatment unable to be recovered or stabilized to grade 1 or below except alopecia (common terminology criteria on adverse event version 4.03 (CTCAE 4.03));
- •Hemotology and coagulation abnormal defined in protocol;
- •Hepatic function abnormal defined in protocol;
- •Renal function abnormal defined in protocol;
- •Cholesterol > 300 mg/dl or 7.75 mmol/L, and/or triglyceride > 2.5 × ULN;
- •Previous history of type 1 or 2 diabetes, or abnormal fasting blood glucose >126 mg/dL(>7 mmol/L) at screening;
- •Cardiovascular system diseases;
- •Patients with active upper peptic ulcer, refractory nausea and vomiting, or other conditions that were known to affect absorption, distribution, metabolism or elimination of drugs;
- •Patients with chronic obstructive emphysema, pulmonary fibrosis or pneumonia that could significantly affect pulmonary function at discretion of the investigator;
- •Infectious Diseases defined in protocol;
- •Judged by the investigator, any other serious or uncontrolled acute or chronic disease, or laboratory abnormality (including but not limited to cardiovascular, hepatic and renal, as well as neuromuscular system), and alcohol consumption, drug abuse that could possibly increase the risk for study or interfere with study conduction and result analysis;
- •Pregnant or lactating women;
- •Previous enrollment in this study or participation in this investigational therapy;
- •Participation in other clinical study during the last 30 days prior to Visit 1
- •At discretion of the Investigator, the patient is unsuitable for participation in this study for any reasons;
- •Patient of poor compliance.
- •Combined with Exemestane period
- •Previous antitumor therapy or any surgical operation within 4 weeks prior to administration of the first dose of study drug;
- •Treatment with myeloid hematopoietic growth factor within two weeks prior to use of investigational product;
- •Patients receiving corticosteroids or immunosuppressive agents within 4 weeks prior to administration of the first dose of study drug;
- •Use of potent-to-moderate cytochrome metabolism enzyme CYP3A4 inhibitor and inducer prior to treatment or during washout period
- •Previous use of Exemestane tablet;
- •Known allergy to LXI-15029 or similar products (mTOR inhibitor or dual mTOR inhibitor) or other component of LXI-15029;
- •Previous or receiving of PI3K or mTOR inhibitors (e.g., BKM120, everolimus, AZD8055 or AZD2014, etc.;
- •Visceral crisis of breast cancer, not suitable for endocrine therapy;
- •Inflammatory breast cancer;
- •History, symptoms or signs of spinal compression, brain metastasis or meningeal metastasis, or manifestations of edema or progression in radiology;
- •History of other tumors within 5 years, except cured carcinoma in situ of cervix or cutaneous basal cell carcinoma;
- •Exclusion criteria on concomitant disease and organ function:
- •The toxicity induced by treatment unable to be recovered or stabilized to grade 1 or below except alopecia (CTCAE 4.03);
- •Hemotology and coagulation abnormal defined in protocol;
- •Hepatic function abnormal defined in protocol;
- •Renal function abnormal defined in protocol;
- •Cholesterol > 300 mg/dl or 7.75 mmol/L, and/or triglyceride > 2.5 × ULN;
- •Previous history of type 1 or 2 diabetes, or abnormal fasting blood glucose >126 mg/dL(>7 mmol/L) at screening;
- •Cardiovascular system abnormal defined in protocol;
- •Patients with active upper peptic ulcer, refractory nausea and vomiting, or other conditions that were known to affect absorption, distribution, metabolism or elimination of drugs;
- •Patients with chronic obstructive emphysema, pulmonary fibrosis or pneumonia that could significantly affect pulmonary function at discretion of the investigator;
- •Infectious Diseases defined in protocol;
- •Judged by the investigator, any other serious or uncontrolled acute or chronic disease, or laboratory abnormality, and alcohol consumption, drug abuse that could possibly increase the risk for study or interfere with study conduction and result analysis;
- •Previous enrollment in this study or participation in this investigational therapy;
- 另有 3 项未显示
研究组 & 干预措施
LXI-15029
Experimental
干预措施: LXI-15029 (Drug)
LXI-15029+Exemestane
Experimental
干预措施: LXI-15029+Exemestane (Drug)
结局指标
主要结局
Number of participants with adverse events
时间窗: When subject complete 1 cycle (28 days) treatment with safety and tolerability assessment by investigators.
To evaluate the safety and tolerability of LXI-15029 through evaluation of the incidence and severity of adverse event (Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE, 4.03))
次要结局
- Area Under the Curve (AUC)(When subject complete 1 cycle (28 days) treatment)
- Tmax(When subject complete 1 cycle (28 days) treatment)
- Maximum Concentration (Cmax)(When subject complete 1 cycle (28 days) treatment)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy SubjectsT2DM (Type 2 Diabetes Mellitus)NCT05369078Newsoara Biopharma Co., Ltd.16
已完成
1 期
A Phase I Study of LEE011 in Asian PatientsAdvanced Solid TumorsNCT01898845Novartis Pharmaceuticals17
终止
1 期
Clinical Study of KN052 in Chinese Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT05309512Jiangsu Alphamab Biopharmaceuticals Co., Ltd15
已完成
1 期
Study of XL999 in Adults With Solid TumorsCancerNCT00104117Symphony Evolution, Inc.52
招募中
1 期
To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR MutationNon-small Cell Lung CancerNCT05555212Qilu Pharmaceutical Co., Ltd.72